Short-term treatment with olanzapine does not modulate gut hormone secretion: Olanzapine disintegrating versus standard tablets

European Journal of Endocrinology

Volumn 162, Issue 1, 2010, Pages 75-83

  Vidarsdottir, Solrun ^a   Roelfsema, Ferdinand ^a   Streefland, Trea ^a   Holst, Jens J ^b   Rehfeld, Jens F ^c   Pijl, Hanno ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; OLANZAPINE; PANCREAS POLYPEPTIDE; PEPTIDE YY; BENZODIAZEPINE DERIVATIVE; PEPTIDE HORMONE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DRUG DOSAGE FORM COMPARISON; HORMONE RELEASE; HUMAN; INSULIN SENSITIVITY; MALE; MEAL; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; TABLET; WEIGHT GAIN; BLOOD; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DIET RESTRICTION; DRUG EFFECT; ENTEROENDOCRINE CELL; SECRETION; TREATMENT OUTCOME;

ADULT; BENZODIAZEPINES; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; ENTEROENDOCRINE CELLS; FASTING; HUMANS; MALE; PEPTIDE HORMONES; TABLETS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73949102385     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0433     Document Type: Article

References (48)

1. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA & Goff DC. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. American Journal of Psychiatry 2000 157 975-981.
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC & Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999 156 1686-1696.
3. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. Journal of Clinical Psychiatry 2004 65 36-46.
4. Arranz B, San L, Duenas RM, Centeno M, Ramirez N, Salavert J & Del Moral E. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Human Psychopharmacology 2007 22 11-15.
5. de Haan L, van Amelsvoort T, Rosien K & Linszen D. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology 2004 175 389-390.
6. Markowitz JS, DeVane CL, Malcolm RJ, Gefroh HA, Wang JS, Zhu HJ & Donovan JL. Pharmacokinetics of olanzapine after singledose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. Journal of Clinical Pharmacology 2006 46 164-171.
7. Bergstrom RF, Mitchell M, Witcher J, Houston JP, Hill AL, Taylor CC, Liu-Seifert H, Yadav Marya R & Jones B. Rapid onset of absorption with olanzapine orally disintegrating tablets. Endocrine Society 2005. 2005 (Ref Type: Abstract).
8. Grundy D & Schemann M. Enteric nervous system. Current Opinion in Gastroenterology 2005 21 176-182.
9. Cummings DE & Overduin J. Gastrointestinal regulation of food intake. Journal of Clinical Investigation 2007 117 13-23.
10. Rindi G, Necchi V, Savio A, Torsello A, Zoli M, Locatelli V, Raimondo F, Cocchi D & Solcia E. Characterisation of gastric ghrelin cells in man and other mammals: studies in adult and fetal tissues. Histochemistry and Cell Biology 2002 117 511-519.
11. Anini Y, Hansotia T & Brubaker PL. Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats. Endocrinology 2002 143 2420-2426.
12. Anini Y & Brubaker PL. Muscarinic receptors control glucagonlike peptide 1 secretion by human endocrine L cells. Endocrinology 2003 144 3244-3250.
13. Zhang T, Uchida T, Gomez G, Lluis F, Thompson JC & Greeley GH Jr. Neural regulation of peptide YY secretion. Regulatory Peptides 1993 48 321-328.
14. Orskov C, Rabenhoj L, Wettergren A, Kofod H & Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994 43 535-539.
15. Holst JJ, Christiansen J & Kuhl C. The enteroglucagon response to intrajejunal infusion of glucose, triglycerides, and sodium chloride, and its relation to jejunal inhibition of gastric acid secretion in man. Scandinavian Journal of Gastroenterology 1976 11 297-304.
16. Holst JJ. Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochemistry Journal 1982 207 381-388.
17. Rehfeld JF. Accurate measurement of cholecystokinin in plasma. Clinical Chemistry 1998 44 991-1001.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
19. Vidarsdottir S, Roelfsema F, Frolich M & Pijl H. Olanzapine shifts the temporal relationship between the daily acrophase of serum prolactin and cortisol concentrations rhythm in healthy men. Psychoneuroendocrinology 2009 34 705-712.
20. Vidarsdottir S, Vlug P, Roelfsema F, Frolich M & Pijl H. Orally disintegrating and standard olanzapine tablets similarly elevate the HOMA insulin resistance index and plasma triglyceride levels in healthy men. Journal of Clinical Psychiatry (In Press).
21. Ao Y, Go VL, Toy N, Li T, Wang Y, Song MK, Reeve JR Jr, Liu Y & Yang H. Brainstem thyrotropin-releasing hormone regulates food intake through vagal-dependent cholinergic stimulation of ghrelin secretion. Endocrinology 2006 147 6004-6010.
22. Deacon CF.What do we know about the secretion and degradation of incretin hormones? Regulatory Peptides 2005 128 117-124.
23. Greenberg GR, Chan B, Nordgren SR & Alleyne J. Effect of vagal blockade on food- and hormone-stimulated release of pancreatic polypeptide and motilin in dogs. Digestive Diseases and Sciences 1985 30 946-953.
24. Murashita M, Kusumi I, Inoue T, Takahashi Y, Hosoda H, Kangawa K & Koyama T. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 2005 30 106-110.
25. Palik E, Birkas KD, Faludi G, Karadi I & Cseh K. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Research and Clinical Practice 2005 68 S60-S64.
26. Himmerich H, Fulda S, Kunzel HE, Pfennig A, Dzaja A, Cummings DE & Pollmacher T. Ghrelin plasma levels during psychopharmacological treatment. Neuropsychobiology 2005 52 11-16.
27. Theisen FM, Gebhardt S, Bromel T, Otto B, Heldwein W, Heinzel-Gutenbrunner M, Krieg JC, Remschmidt H, Tschop M & Hebebrand J. A prospective study of serum ghrelin levels in patients treated with clozapine. Journal of Neural Transmission 2005 112 1411-1416.
28. Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y, Kanai A, Kase A, Uchikado H & Hirayasu Y. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. Journal of Psychopharmacology 2006 20 75-79.
29. Togo T, Hasegawa K, Miura S, Hosojima H, Kojima K, Shoji M, Kase A, Uchikado H, Iseki E & Kosaka K. Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology 2004 172 230-232.
30. Barkan AL, Dimaraki EV, Jessup SK, Symons KV, Ermolenko M & Jaffe CA. Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels. Journal of Clinical Endocrinology and Metabolism 2003 88 2180-2184.
31. Weickert MO, Mohlig M, Spranger J, Schofl C, Loeffelholz CV, Riepl RL, Otto B & Pfeiffer AF. Effects of euglycemic hyperinsulinemia and lipid infusion on circulating cholecystokinin. Journal of Clinical Endocrinology and Metabolism 2008 93 2328-2333.
32. Wang Q & Huang XF. Effects of chronic treatment of olanzapine and haloperidol on peptide YY binding densities in the rat brain. Experimental Neurology 2008 209 261-267.
33. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. Journal of Clinical Psychiatry 1999 60 5-14.
34. Holst JJ, Schwartz TW, Lovgreen NA, Pedersen O & Beck-Nielsen H. Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. International Journal of Obesity 1983 7 529-538.
35. Le QA, Kervran A, Blache P, Ciurana AJ & Bataille D. Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone. Journal of Clinical Endocrinology and Metabolism 1992 74 1405-1409.
36. Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, Wren AM, Frost GS, Meeran K, Ghatei MA & Bloom SR. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005 54 2390-2395.
37. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS & Bloom SR. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. International Journal of Obesity 2006 30 1729-1736.
38. Dakin CL, Small CJ, Park AJ, Seth A, Ghatei MA & Bloom SR. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. American Journal of Physiology. Endocrinology and Metabolism 2002 283 E1173-E1177.
39. Geary N. Pancreatic glucagon signals postprandial satiety. Neuroscience and biobehavioral reviews 1990 14 323-338.
40. Theisen FM, Haberhausen M, Firnges MA, Gregory P, Reinders JH, Remschmidt H, Hebebrand J & Antel J. No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics Journal 2007 7 275-281.
41. Crocq MA, Guillon MS, Bailey PE & Provost D. Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets. European Psychiatry 2007 22 453-454.
42. Chawla B & Luxton-Andrew H. Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial. Human Psychopharmacology 2008 23 211-216.
43. Masaki T, Chiba S, Yasuda T, Noguchi H, Kakuma T, Watanabe T, Sakata T & Yoshimatsu H. Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes 2004 53 2250-2260.
44. Nonogaki K, Strack AM, Dallman MF & Tecott LH. Leptinindependent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nature Medicine 1998 4 1152-1156.
45. Pijl H. Reduced dopaminergic tone in hypothalamic neural circuits: expression of a "thrifty" genotype underlying the metabolic syndrome? European Journal of Pharmacology 2003 480 125-131.
46. Wellman PJ, Davies BT, Morien A & McMahon L. Modulation of feeding by hypothalamic paraventricular nucleus alpha 1- and alpha 2-adrenergic receptors. Life Sciences 1993 53 669-679.
47. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J & Marder SR. Novel antipsychotics: comparison of weight gain liabilities. Journal of Clinical Psychiatry 1999 60 358-363.
48. Meier A & Cincotta AH. Circadian rhythms regulate the expression of the thrifty genotype/phenotype. Diabetes Reviews 1996 4 464-487.